Vol. 4 No. 10 (2024)
Reimbursement Reviews

Relugolix (Orgovyx)

decorative image of the issue cover

Published October 28, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses relugolix, (Orgovyx), 120 mg, oral tablets.
  • Indication: For the treatment of adult patients with advanced prostate cancer.